{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:10:20Z","timestamp":1793419820931,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003186","name":"National Rosacea Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003186","name":"National Rosacea Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003186","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aclaris Therapeutics","id":[{"id":"https:\/\/ror.org\/00q1zbc26","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer","id":[{"id":"https:\/\/ror.org\/04hmn8g73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Cutanea Life Sciences, Inc"},{"name":"Galderma Laboratories"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jaad.2020.01.077","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T03:22:29Z","timestamp":1581045749000},"page":"1501-1510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":218,"title":["Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee"],"prefix":"10.1016","volume":"82","author":[{"given":"Diane","family":"Thiboutot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rox","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Cook-Bolden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Draelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Granstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sewon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Macsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda Stein","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.01.077_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","article-title":"Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee","volume":"78","author":"Gallo","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib2","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.jaad.2018.08.049","article-title":"Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience","volume":"80","author":"Alexis","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib3","first-page":"282","article-title":"Incidence and prevalence of rosacea: a systematic review and meta-analysis","volume":"179","author":"Gether","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib4","first-page":"47","article-title":"Rosacea and demodicosis: little-known diagnostic signs and symptoms","volume":"99","author":"Forton","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.01.077_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2133.2010.09894.x","article-title":"The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities","volume":"163","author":"Aksoy","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpp.763","article-title":"Blushing propensity and psychological distress in people with rosacea","volume":"19","author":"Su","year":"2012","journal-title":"Clin Psychol Psychother"},{"key":"10.1016\/j.jaad.2020.01.077_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13555-015-0077-2","article-title":"Perceptions on the psychological impact of facial erythema associated with rosacea: results of international survey","volume":"5","author":"Dirschka","year":"2015","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2020.01.077_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/00015555-1976","article-title":"Health-related quality of life in patients with cutaneous rosacea: a systematic review","volume":"95","author":"Van der Linden","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.01.077_bib12","first-page":"120","article-title":"Results of a national rosacea patient survey: common issues that concern rosacea sufferers","volume":"8","author":"Elewski","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s13555-016-0106-9","article-title":"Erythema of rosacea\u00a0impairs health-related quality of life: results of a meta-analysis","volume":"6","author":"Bewley","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2020.01.077_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jdv.13748","article-title":"Feelings of stigmatization in patients with rosacea","volume":"31","author":"Haliou","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.077_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0039-6257(86)90034-2","article-title":"Ocular rosacea","volume":"31","author":"Browning","year":"1986","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jaad.2020.01.077_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1590\/S0004-27492012000500016","article-title":"Ocular rosacea \u2013 a review","volume":"75","author":"Vieira","year":"2012","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.jaad.2020.01.077_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jaad.2015.04.028","article-title":"Cardiovascular comorbidities in patients with rosacea: a nationwide case-control study from Taiwan","volume":"73","author":"Hua","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib18","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/jdv.12234","article-title":"Rosacea and cardiovascular risk factors: a case control study","volume":"28","author":"Duman","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.077_bib19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaad.2016.02.1158","article-title":"Assessment of the risk of cardiovascular disease in patients with rosacea","volume":"75","author":"Egeberg","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.01.077_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjd.14930","article-title":"Rosacea and gastrointestinal disorders: a population-based cohort study","volume":"176","author":"Egeberg","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40257-016-0217-1","article-title":"Nationwide assessment of cause-specific mortality in patients with rosacea: a cohort study in Denmark","volume":"17","author":"Egeberg","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MIB.0000000000000644","article-title":"Rosacea in patients with ulcerative colitis and Crohn's disease: a population-based case control study","volume":"22","author":"Spoendlin","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2020.01.077_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2016.08.022","article-title":"Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population-based cross-sectional study","volume":"76","author":"Kim","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2015.07.009","article-title":"Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study","volume":"73","author":"Rainer","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaneurol.2016.0022","article-title":"Exploring the\u00a0association between rosacea and Parkinson disease: a\u00a0Danish nationwide cohort study","volume":"73","author":"Egeberg","year":"2016","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.jaad.2020.01.077_bib26","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.jid.2016.05.015","article-title":"LB766 Parkinson's disease association with rosacea: a large, single center, retrospective study","volume":"136","author":"Lyon","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ana.24645","article-title":"Patients with rosacea have increased risk of dementia","volume":"79","author":"Egeberg","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaad.2020.01.077_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2015.11.004","article-title":"Clustering of autoimmune diseases in patients with rosacea","volume":"74","author":"Egeberg","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1684\/ejd.2016.2748","article-title":"The relationship between rosacea and insulin resistance and metabolic syndrome","volume":"26","author":"Akin Belli","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2020.01.077_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaad.2016.08.055","article-title":"Prevalence and risk of migraine in patients with rosacea: a population-based cohort study","volume":"76","author":"Egeberg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib31","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/bjc.2015.217","article-title":"Personal history of rosacea and risk of incident cancer among women in the US","volume":"113","author":"Li","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2020.01.077_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamadermatol.2015.5549","article-title":"Association of rosacea with risk for glioma in a Danish nationwide cohort study","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","article-title":"Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea","volume":"46","author":"Wilkin","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib34","first-page":"907","article-title":"Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea","volume":"50","author":"Wilkin","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/09546634.2017.1343435","article-title":"Defining treatment success in rosacea as \u2018clear\u2019 may provide multiple patient benefits: results of a pooled analysis","volume":"28","author":"Webster","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2020.01.077_bib36","first-page":"CD003262","article-title":"Interventions for rosacea","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2020.01.077_bib37","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the\u00a0treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib38","series-title":"Rhofade cream prescribing information","year":"2017"},{"key":"10.1016\/j.jaad.2020.01.077_bib39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","article-title":"Rosacea \u2013 global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group","volume":"25","author":"Elewski","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.077_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bjd.15173","article-title":"Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel","volume":"176","author":"Schaller","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMcp042829","article-title":"Clinical practice. Rosacea","volume":"352","author":"Powell","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.01.077_bib42","first-page":"768","article-title":"Rosacea \u2013 S1 guideline","volume":"11","author":"Reinholz","year":"2013","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2020.01.077_bib43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1203475416650427","article-title":"Canadian clinical practice guidelines for rosacea","volume":"20","author":"Asai","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2020.01.077_bib44","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib45","first-page":"1380","article-title":"Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials","volume":"13","author":"Stein Gold","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/jdv.13537","article-title":"Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-233k extension of the ATTRACT randomized study","volume":"30","author":"Taieb","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.01.077_bib47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaad.2019.05.063","article-title":"A randomized phase 3b\/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea","volume":"82","author":"Schaller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib49","first-page":"306","article-title":"Azelaic acid foam\u00a015% in the treatment of papulopustular rosacea: a\u00a0randomized, double-blind, vehicle-controlled study","volume":"92","author":"Draelos","year":"2013","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.jaad.2020.01.077_bib50","article-title":"A multi-center, investigator-blind clinical trial to assess the safety and efficacy of metronidazole gel 1% as compared to metronidazole gel vehicle and metronidazole cream 1% in the treatment of rosacea","volume":"52","author":"Beutner","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF03259203","article-title":"A double-blind randomized study of metronidazole (Flagyl) 1% cream in the treatment of acne rosacea","volume":"2","author":"Bitar","year":"1990","journal-title":"Drug Invest"},{"key":"10.1016\/j.jaad.2020.01.077_bib52","first-page":"187","article-title":"Metronidazole (Elyzol) 1% cream v. placebo cream in the treatment of rosacea","volume":"26","author":"Bjerke","year":"1989","journal-title":"Clin Trials J"},{"key":"10.1016\/j.jaad.2020.01.077_bib53","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.1987.01660290077020","article-title":"Topical metronidazole therapy for rosacea","volume":"123","author":"Bleicher","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib54","first-page":"44","article-title":"A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea","volume":"61","author":"Breneman","year":"1998","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2020.01.077_bib55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archderm.134.6.679","article-title":"Topical metronidazole maintains remissions of rosacea","volume":"134","author":"Dahl","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib56","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000065849","article-title":"Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea: a randomized double-blind placebo-controlled study","volume":"205","author":"Ko\u00e7ak","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2020.01.077_bib57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2133.1983.tb03972.x","article-title":"Treatment of rosacea with 1% metronidazole cream: a double-blind study","volume":"108","author":"Nielsen","year":"1983","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.01.077_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjd.17590","article-title":"Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments","volume":"181","author":"van Zuuren","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib59","first-page":"909","article-title":"Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study","volume":"16","author":"Stein Gold","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib60","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib61","first-page":"573","article-title":"Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea","volume":"7","author":"Del Rosso","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib62","first-page":"505","article-title":"Systemic isotretinoin in the treatment of rosacea \u2013 doxycycline- and placebo-controlled, randomized clinical study","volume":"8","author":"Gollnick","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2020.01.077_bib63","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jid.2016.01.025","article-title":"A randomized-controlled trial of oral low-dose isotretinoin for difficult-to-treat papulopustular rosacea","volume":"136","author":"Sbidian","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib64","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(71)90376-X","article-title":"Comparative effectiveness of tetracycline and\u00a0ampicillin in rosacea: a controlled trial","volume":"2","author":"Marks","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.01.077_bib65","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.1966.tb12168.x","article-title":"A clinical trial of tetracycline in rosacea","volume":"78","author":"Sneddon","year":"1966","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib66","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaad.2014.08.027","article-title":"Rosacea: Part II. Topical and systemic therapies in the treatment of rosacea","volume":"72","author":"Two","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2020.01.077_bib67","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1444-0938.2010.00540.x","article-title":"Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis","volume":"94","author":"Opitz","year":"2011","journal-title":"Clin Exp Optom"},{"issue":"1","key":"10.1016\/j.jaad.2020.01.077_bib68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/ICO.0b013e318254205f","article-title":"Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study","volume":"32","author":"Foulks","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.jaad.2020.01.077_bib69","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2017.0095","article-title":"Comparison of the clinical efficacy of topical and systemic azithromycin treatment for posterior blepharitis","volume":"34","author":"Yildiz","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jaad.2020.01.077_bib70","first-page":"1016","article-title":"Comparison of therapeutic effects of topical azithromycin solution and systemic doxycycline on posterior blepharitis","volume":"9","author":"Zandian","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jaad.2020.01.077_bib71","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/ceo.12793","article-title":"Meibomian gland dysfunction: azithromycin and objective improvement in outcomes in posterior blepharitis","volume":"44","author":"Shah","year":"2016","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jaad.2020.01.077_bib72","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/ICO.0000000000000051","article-title":"Treatment of ocular rosacea with once-daily low-dose doxycycline","volume":"33","author":"Sobolewska","year":"2014","journal-title":"Cornea"},{"key":"10.1016\/j.jaad.2020.01.077_bib73","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1997.03890370055009","article-title":"Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline","volume":"133","author":"Quarterman","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib74","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ophtha.2015.10.062","article-title":"Oral antibiotics for meibomian gland-related ocular surface disease: a report by the American Academy of Ophthalmology","volume":"123","author":"Wladis","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaad.2020.01.077_bib75","first-page":"97","article-title":"Standard management options for rosacea, part 2: options according to subtype","volume":"84","author":"Odom","year":"2009","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2020.01.077_bib76","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMcp1506630","article-title":"Rosacea","volume":"377","author":"van Zuuren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.01.077_bib77","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","article-title":"Neurovascular and neuroimmune aspects in the pathophysiology of rosacea","volume":"15","author":"Schwab","year":"2011","journal-title":"J Invest Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2020.01.077_bib78","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2353\/ajpath.2010.090941","article-title":"Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in\u00a0vivo","volume":"177","author":"Seeliger","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2020.01.077_bib79","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/jid.2011.424","article-title":"Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea","volume":"132","author":"Sulk","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib80","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/IOP.0b013e31824dd9d4","article-title":"Molecular biologic assessment of cutaneous specimens of ocular rosacea","volume":"28","author":"Wladis","year":"2012","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.jaad.2020.01.077_bib81","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12385","article-title":"An observational cross-sectional survey of rosacea: clinical associations and\u00a0progression between subtypes","volume":"169","author":"Tan","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib82","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/exd.13143","article-title":"Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics","volume":"26","author":"Holmes","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib83","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","article-title":"Clinical, cellular, and molecular aspects in the pathophysiology of rosacea","volume":"15","author":"Steinhoff","year":"2011","journal-title":"J Invest Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2020.01.077_bib84","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.jid.5700213","article-title":"Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling","volume":"126","author":"Trivedi","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib85","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/jid.2015.141","article-title":"Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1\/Th17 pathways","volume":"135","author":"Buhl","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib86","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/jidsymp.2011.8","article-title":"Neurovascular aspects of skin neurogenic inflammation","volume":"15","author":"Aubdool","year":"2011","journal-title":"J Invest Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2020.01.077_bib87","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/000155599750009915","article-title":"Stinging and rosacea","volume":"79","author":"Lonne-Rahm","year":"1999","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.01.077_bib88","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2013","article-title":"Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease","volume":"94","author":"Steinhoff","year":"2014","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jaad.2020.01.077_bib89","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1167\/iovs.05-0275","article-title":"High prevalence of Demodex in eyelashes with cylindrical dandruff","volume":"46","author":"Gao","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaad.2020.01.077_bib90","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2014.222","article-title":"Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea","volume":"134","author":"Muto","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib91","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/jid.2010.351","article-title":"TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes","volume":"131","author":"Yamasaki","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib92","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1600-0625.2008.00768.x","article-title":"The vitamin D pathway: a new target for control of the skin's immune response?","volume":"17","author":"Schauber","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib93","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","article-title":"Increased serine\u00a0protease activity and cathelicidins promotes skin inflammation in rosacea","volume":"13","author":"Yamasaki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2020.01.077_bib94","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1600-051X.2004.00558.x","article-title":"Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis: a review","volume":"31","author":"Preshaw","year":"2004","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.jaad.2020.01.077_bib95","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as\u00a0maintenance monotherapy","volume":"8","author":"Thiboutot","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib96","first-page":"30","article-title":"The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients","volume":"4","author":"Shim","year":"2013","journal-title":"J Clin Aesth Dermatol"},{"key":"10.1016\/j.jaad.2020.01.077_bib97","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jaad.2004.04.010","article-title":"Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life","volume":"51","author":"Tan","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2020.01.077_bib98","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jtos.2018.11.004","article-title":"Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction","volume":"17","author":"Arita","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jaad.2020.01.077_bib99","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/02713683.2018.1536217","article-title":"Therapeutic effect of intense pulsed light on ocular demodicosis","volume":"44","author":"Zhang","year":"2019","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jaad.2020.01.077_bib100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3109\/14764172.2011.613480","article-title":"Intense pulsed light for the treatment of rosacea and telangiectasias","volume":"13","author":"Kassir","year":"2011","journal-title":"J Cosmet Laser Ther"},{"issue":"4","key":"10.1016\/j.jaad.2020.01.077_bib101","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/ICU.0000000000000166","article-title":"Intense pulsed light therapy for the treatment of evaporative dry eye disease","volume":"26","author":"Vora","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jaad.2020.01.077_bib102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/pho.2014.3819","article-title":"Intense pulsed light treatment\u00a0for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study","volume":"33","author":"Toyos","year":"2015","journal-title":"Photomed Laser Surg"},{"issue":"2","key":"10.1016\/j.jaad.2020.01.077_bib103","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jtos.2013.12.001","article-title":"Evaluation of an\u00a0automated thermodynamic treatment (LipiFlow\u00ae) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial","volume":"12","author":"Finis","year":"2014","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jaad.2020.01.077_bib104","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jcjo.2016.01.005","article-title":"Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease","volume":"51","author":"Gupta","year":"2016","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jaad.2020.01.077_bib105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/OPTH.S150433","article-title":"Comparison of a single-dose vectored thermal pulsation procedure with a 3-month course of daily oral doxycycline for moderate-to-severe meibomian gland dysfunction","volume":"17","author":"Hagen","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jaad.2020.01.077_bib106","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/02713683.2017.1406525","article-title":"Changes in the meibomian gland after exposure to intense pulsed light in meibomian gland dysfunction (MGD) patients","volume":"43","author":"Yin","year":"2019","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jaad.2020.01.077_bib107","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1089\/pho.2017.4402","article-title":"Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction","volume":"36","author":"Rong","year":"2018","journal-title":"Photo Med Laser Surg"},{"key":"10.1016\/j.jaad.2020.01.077_bib108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/OPTH.S153297","article-title":"A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day","volume":"12","author":"Blackie","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jaad.2020.01.077_bib110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/phpp.12214","article-title":"Metal oxide sunscreens protect\u00a0skin by absorption, not by reflection or scattering","volume":"32","author":"Cole","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220301663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220301663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:56:20Z","timestamp":1759272980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220301663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0190962220301663"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.01.077","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.01.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}